Unknown Manufacturer
AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia for patients experiencing acute pain episodes. AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain.
AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia for patients experiencing acute pain episodes. AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain.
AeroLEF is developed to offer a simple and non-invasive route of administration, rapid onset of action, sustained effect and self-titratable dosing for the treatment of acute and breakthrough pain, conditions that are common in cancer patients and underserved by existing fixed-dose delivery technologies. Using AeroLEF, patients can identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.
Investigated for use/treatment in pain (acute or chronic).
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
